XERIS BIOPHARMA HOLDINGS, INC. Net Change in Cash
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Net Change in Cash of $10.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $708.00K.
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$13.18M.
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$4.76M.
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$70.98M, a 294.47% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $39.32M, a 866.07% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $4.07M.
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$54.64M, a 192.54% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $59.04M, a 98.98% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.71M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $708.00K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $39.32M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $19.88M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$12.34M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$13.18M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $4.07M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$8.32M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$9.85M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$4.76M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$54.64M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | -$75.75M 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | -$75.72M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$70.98M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $59.04M 10-K · filed 2025-03-06 | |||
| 2022-09-30 | $16.84M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $28.07M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $36.50M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $29.67M 10-K · filed 2024-03-06 | |||
| 2021-09-30 | $21.89M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $26.00M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $29.01M 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |